Department of Radiology and Radiological Sciences Presents the
12th Annual Martin P. Sandler Lecture in Nuclear Medicine and Molecular Imaging
Richard L. Wahl, M.D.
Elizabeth Mallinckrodt Professor, Radiology
Chairman, Department of Radiology
Director, Mallinckrodt Institute of Radiology
Washington University School of Medicine in St. Louis
St. Louis, Missouri
Monday, June 10, 2019 | Noon - 1 p.m.
This grand rounds lecture is designed for faculty, residents, staff and medical students.
Learning objectives of this presentation include:
- The use of PET SUV in planning and assessing treatment
- The use of quantitative SPECT to plan patient-specific theranostic procedures
- How "underutilization" of imaging may lead to over utilization of therapies
- How the phenotype (phenome) complements the genotype in precision medicine
Richard L. Wahl, M.D., is the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, director of the university’s Mallinckrodt Institute of Radiology and professor of radiation oncology. He previously served as the first Henry N. Wagner Jr. Professor of Nuclear Medicine at Johns Hopkins and as a professor at the University of Michigan.
After graduating from Washington University School of Medicine and serving his residency there, Wahl interned at the University of California at San Diego School of Medicine. He returned to Washington University in 1979 for training in diagnostic radiology and nuclear medicine.
Wahl’s research played an important role in the development of radioimmunotherapy for non-Hodgkin's lymphoma. He has also been a pioneer in the use of PET scans to diagnose and assess treatment of a broad array of human cancers and other diseases, and he is at the forefront of efforts to combine quantitative data from PET scans with computerized tomography (CT) to form “fusion” images that can help physicians more precisely diagnose and characterize cancers. Wahl and colleagues developed the PERCIST 1.0 criteria for assessing treatment response in cancer.
Wahl is also a world-renowned leader in molecular imaging and therapy. Over the past 35 years, his contributions have touched nearly every aspect of the field and spans from the bench to the bedside. Dr. Wahl's strong research and clinical interest contributions in radionuclide therapy led to the development of radiolabeled antibodies for the treatment of lymphoma and the translation of this therapy to patients.
Wahl is an elected member of the National Academy of Medicine and has received honors from multiple organizations. He holds 18 patents and has published more than 400 peer-reviewed scientific manuscripts. He is the primary author of several textbooks, including Principles and Practice of PET and PET/CT. He has a strong interest in quantitative imaging, is on the coordinating committee of the Quantitative Imaging Biomarkers Alliance (QIBA) efforts of the Radiological Society of North America and has been a lead investigator in the Quantitative Imaging Network (QIN) of the National Institutes of Health. At the SNMMI 2018 annual meeting, he was awarded both the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine as well as the Saul Hertz, MD Lifetime Achievement Award for outstanding contributions to radionuclide therapy.